Sanj K. Patel, President & CEO at SYNAGEVA BIOPHARMA CORP (GEVA), sold 60,000 shares at $45.12 ($2.8M) on 2012-12-13, disclosed to the SEC on 2012-12-17.
Scheduled sale ($2.8M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.12 | 8,399 | $379K | 13.7% |
| 2 | $45.87 | 3,300 | $151K | 5.5% |
| 3 | $47.07 | 2,701 | $127K | 4.6% |
| 4 | $45.30 | 13,281 | $602K | 21.7% |
| 5 | $45.97 | 7,004 | $322K | 11.6% |
| 6 | $47.03 | 23,715 |
| $1.1M |
| 40.2% |
| 7 | $47.53 | 1,600 | $76K | 2.7% |
| Total | $46.21 avg | 60,000 | $2.8M | 100% |
| Filing → |
| KNSA | SELL | 2026-04-08 | $364K | — | Filing → |
| KNSA | SELL | 2025-10-22 | $20.0M | — | Filing → |
| KNSA | SELL | 2025-05-28 | $4.6M | — | Filing → |